Standard BioTools
LAB
80 hedge funds and large institutions have $154M invested in Standard BioTools in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 11 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
23% more call options, than puts
Call options by funds: $342K | Put options by funds: $278K
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
0.52% more ownership
Funds ownership: 92.38% → 92.9% (+0.52%)
4% less funds holding
Funds holding: 83 → 80 (-3)
21% less capital invested
Capital invested by funds: $196M → $154M (-$41.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$11.5M |
| 2 |
Neuberger Berman Group
New York
|
+$4.48M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.23M |
| 4 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$1.74M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$7.75M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$5.82M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.17M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$317K |
| 5 |
Morgan Stanley
New York
|
-$290K |
LAB Hedge Fund Activity: Q1 2017 in Review
80 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2017, worth a combined $154M — down 21% from $196M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new LAB positions and 11 closed out — a net gain of 2 holders — while 29 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $11.5M. The largest seller was Wasatch Advisors, cutting an estimated $7.75M.
- 80 institutional investors held Standard BioTools (LAB) as of Q1 2017, down from 83 in Q4 2016.
- Funds reported $154M of Standard BioTools stock for Q1 2017, down 21% quarter-over-quarter.
- 13 funds opened new Standard BioTools positions in Q1 2017 and 11 closed out, a net change of +2 holders.
- The largest Standard BioTools buyer in Q1 2017 was BlackRock, an estimated $11.5M added.
- The largest Standard BioTools seller in Q1 2017 was Wasatch Advisors, an estimated $7.75M sold.
Based on aggregated 13F filings for Q1 2017.